Accès au site français Welcome to You buy France The french suppliers portal


twitter linkedin facebook viadeo

You buy France


In-Cell-Art (ICA), which is headquartered in Nantes (France) is a biopharmaceutical company specializing in the preclinical and pharmaceutical development of nanocarriers named Nanotaxi ® for macromolecular drugs. Its founder and research team, which includes a Nobel Laureate, have designed new classes of vectors that are organized on a nanometric scale, which enables them to cross the cell barrier efficiently and safely. In-Cell-Art offers a range of reagents and biotechnology development services:

1. ICANtibodies™
In the absence of recombinant antigen, ICANtibodies™ allows, from an in silico DNA antigenic sequence, the production of the most ambitious functional antibodies against any natively expressed nuclear, cytoplasmic, secreted or membrane proteins. ICANtibodies™ has allowed, in less than 2 years, the production of more than 250 different functional antibodies. In-Cell-Art has worked with a number of pharmaceutical firms (Sanofi, GlaxoSmithKline, Geneuro etc.) and public research institutions and universities (Institut Cochin, Cancer Research UK, Institute of Neurology UK etc).

2. ICA Nanotaxi ®
・DNA Vaccine
ICA614 Nanotaxi®, an innovative DNA synthetic formulation, offers unique efficient and industrial features such as the dramatic enhancement of the immunogenicity of plasmid DNA-encoding tumours or pathogen-derived antigens, a reduction in the dose of plasmid DNA, as well as an excellent safety profile. ICA614 Nanotaxi® represents a crucial step in DNA vaccine development, and is currently being tested by major vaccine companies (Sanofi-Pasteur, Merial etc.).
・mRNA Vaccine
Some other ICA Nanotaxi® are also being assessed in $33.1 million RN-ARMORVAX consortium, co-funded by US Defense Advanced Research Projects Agency (DARPA). The consortium would validate the new application of ICA Nanotaxi® for mRNA-based vaccines for infectious diseases in collaboration with CureVac and Sanofi-Pasteur.

3. ICAFectin® transfection reagents
ICAFectin® transfection reagents are innovative breakthrough synthetic vectors for in vitro nucleic acid delivery. They are becoming the reagents of choice for efficient DNA and siRNA transfections as demonstrated by their increasing use in numerous studies published in high impact factor journals including Journal of Biological Chemistry, Nucleic Acids Research, PLOS ONE, PLOS Pathogen, Human Gene Therapy and more.

In-Cell-Art is a privately held company, which was founded in 2005. It is a member of the Atlanpole Biotherapies high-tech cluster of biotechnology companies in western France.

+ Read more


Company profile

Related activities :

Health, pharmacy, life sciences

Export area :

European Union

Near and Middle East

North America

North Asia


Local presence :

European Union

Target countries :


Europe outside E.U.

European Union

North Africa

North America

North Asia


South America

South Asia

More information

Company Products and Services










Business France contributes to the development and success of French and foreign businesses wishing to expand abroad by supporting them throughout the lifetime of their projects, and is driven by an efficient, result-oriented working culture. > Read more


Discover the French know how:



Rail industry